This phase III trial randomized 1836 patients, in a 1:1 ratio, to receive adjuvant olaparib vs. placebo in patients with high-risk clinicopathological features, early HER2-negative breast cancer with a germline BRCA mutation, post-local treatment plus adjuvant/neoadjuvant chemotherapy [11]. This evidence concerns the gene ERBB2 and breast cancer.